BNTX vs NVAX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BNTX and NVAX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BNTX and NVAX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

BioNTech SE is a German biotechnology company, headquartered in Mainz, whose shares trade in the US as an American Depositary Receipt under the ticker BNTX on Nasdaq. It rose to global prominence by co-developing the Comirnaty mRNA COVID-19 vaccine with Pfizer, which generated enormous revenue and a large cash pile at the pandemic's peak. As COVID vaccine demand has normalized, that revenue has fallen sharply, and the company has guided to substantially lower sales than the pandemic years. The investment case has therefore moved away from vaccines and toward whether BioNTech can convert its mRNA and immunotherapy platforms, and its balance sheet, into an oncology franchise.

Full BNTX guide

Novavax is a biotechnology company known for protein-based vaccines and its proprietary Matrix-M adjuvant, a saponin-based compound that boosts the immune response to a vaccine. Its best-known product is Nuvaxovid, a protein-based COVID-19 vaccine that offered an alternative to the mRNA shots from Pfizer and Moderna. After years of manufacturing and cash-burn struggles, Novavax restructured its strategy: rather than carrying the full cost of producing and marketing vaccines itself, it now leans on partners to commercialize its products and licenses its adjuvant technology to others.

Full NVAX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BNTX drivers: Oncology pipeline and pumitamig; Bristol Myers Squibb partnership.
• NVAX drivers: Sanofi partnership and milestones; Matrix-M adjuvant licensing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is clinical: most drug candidates fail, and BioNTech's valuation leans heavily on unproven oncology programs, so disappointing trial data for pumitamig or other assets could sharply cut the stock. For NVAX, novavax remains a speculative small-cap biotech with meaningful risks.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BNTX if you believe its drivers more; NVAX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BNTX and NVAX guides.

BNTX. Figures here are intentionally directional because BioNTech's reported results swing with lumpy COVID vaccine revenue and one-off partnership payments, which distort quarter-to-quarter comparisons. Conventional earnings multiples are of limited use for a company that is currently loss-making and valued largely on its pipeline and cash; a large slice of the market capitalization is effectively backed by its cash and securities balance. What matters most is the probability-weighted value of the oncology programs and how much cash is spent to reach it. Always verify the latest cash balance, guidance, and trial readouts before acting.

NVAX. These figures are approximate and tied to the asOf date; verify live numbers before acting. Novavax's revenue is increasingly lumpy because it depends on one-time milestone and licensing payments that may not repeat quarter to quarter, so a single strong quarter can overstate the run-rate. Traditional earnings multiples are of limited use for a transitioning biotech like this, where the value depends on future partner milestones and royalties rather than steady product sales.

Headline figures (approximate, Jul 2026): BNTX shows listing structure US-listed ADR (BNTX on Nasdaq) of a German company, BioNTech SE, based in Mainz, revenue trend Well below pandemic peaks; 2026 guidance points to a lower, COVID-vaccine-dependent revenue base, profitability Reporting net losses as heavy R&D spending on the oncology pipeline outweighs shrinking vaccine profit, balance sheet Very strong; cash, equivalents, and securities reported in the billions of euros, boosted by the Bristol Myers Squibb upfront; NVAX shows revenue (2026 guidance) ~$230 million to $270 million range guided for full-year 2026, q1 2026 revenue ~$140 million, above expectations, driven largely by partnership and licensing income, revenue mix Weighted toward licensing, royalties, and milestones rather than direct product sales, market cap Small-cap (roughly a low single-digit billion; verify live).

BNTX and NVAX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BNTX and NVAX exposure against your real portfolio. It is not an investment adviser.